Janulionis Ernestas, Valuckas Konstantinas Povilas, Liukpetryte Sarune, Samerdokiene Vitalija, Atkocius Vydmantas
Radiotherapy and Drug Center.
Scientific Research Center, National Cancer Institute, Vilnius, Lithuania.
J Contemp Brachytherapy. 2015 Oct;7(5):346-51. doi: 10.5114/jcb.2015.55117. Epub 2015 Oct 19.
The purpose of this paper was to observe and compare long-term curative effects and complications of FIGO stage IIB cervical cancer patients (n = 232) treated with high-dose-rate (HDR) californium ((252)Cf) neutron or cobalt ((60)Co) photon intracavitary brachytherapy (ICBT) combined with external-beam radiotherapy (EBRT).
The EBRT dose to the small pelvis was 50 Gy in both groups. The brachytherapy component of (252)Cf or (60)Co was added in the 3(rd) week of EBRT, 5 fractions were performed once per week resulting in a total ICBT dose of 40 Gy/Gyeq (point A).
Overall survival (OS) at 5, 10 and 15 years was 63.6%, 50.4% and 38.8% in the (252)Cf group and 62.2%, 50.5%, 39.9%, in the (60)Co group, respectively (p = 0.74). The percentage of tumour recurrence was statistically significantly lower in the (252)Cf group with 7.4% versus 17.1% in the (60)Co group (p = 0.02). Second primary cancers have developed similarly 9.1% and 8.1% cases for (252)Cf and (60)Co groups, respectively.
Our long-term retrospective study comparing (252)Cf and (60)Co isotopes with brachytherapy in combined treatment of FIGO IIB stage cervix carcinoma patients shows, that overall survival in the both groups are similar. However, the recurrence of tumour was significantly lower in the (252)Cf group. The incidence of second primary cancers was similar in both groups.
本文旨在观察和比较国际妇产科联盟（FIGO）IIB期宫颈癌患者（n = 232）接受高剂量率（HDR）锎（²⁵²Cf）中子或钴（⁶⁰Co）光子腔内近距离放射治疗（ICBT）联合体外放射治疗（EBRT）的长期疗效和并发症。
两组患者的小骨盆体外放射治疗剂量均为50 Gy。在体外放射治疗的第3周添加²⁵²Cf或⁶⁰Co的近距离放射治疗部分，每周进行5次，每次1次，腔内近距离放射治疗总剂量为40 Gy/等效剂量（A点）。
²⁵²Cf组5年、10年和15年的总生存率分别为63.6%、50.4%和38.8%，⁶⁰Co组分别为62.2%、50.5%、39.9%（p = 0.74）。²⁵²Cf组肿瘤复发率为7.4%，显著低于⁶⁰Co组的17.1%（p = 0.02）。²⁵²Cf组和⁶⁰Co组分别有9.1%和8.1%的病例发生了第二原发性癌症，情况相似。
我们对FIGO IIB期宫颈癌患者联合治疗中使用²⁵²Cf和⁶⁰Co同位素进行近距离放射治疗的长期回顾性研究表明，两组的总生存率相似。然而，²⁵²Cf组的肿瘤复发率显著较低。两组第二原发性癌症的发生率相似。
